Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma

Phase 2

• Conditions: untreated multiple myeloma

• Registration Number: JPRN-UMIN000009765
• Lead Sponsor: Kanagawa Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-12
• Study Completion: 2018-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1. severe renal damage: Ccr <30mL/min even after correction of dehydration and hypercalcemia 2.severe cardiac dysfunction: angina pectoris or acute myocardial infarction within 6 months of enrollment, congestive heart failure requiring medical treatment or arrhythmia requiring medical treatment. 3.severe respiratory dysfunction: SpO2 <= 93%, interstitial pneumonitis, chronic obstructive pulmonary disease, active pneumonia 4.infection 4-1HIV positive 4-2HBs antigen positive 4-3HBs antibody positive and/or HBc antibody positive and HBV-DNA positive 4-4HCV antibody positive 5.peripheral neuropathy > grade 2 6.Uncontrolled diabetes mellitus 7.others 7-1active double cancer 7-2pregnancy or breastfeeding 7-3doctor judged adequate to enroll the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified